These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 22915619)

  • 1. Rituximab dissociates the tight link between disease activity and joint damage in rheumatoid arthritis patients.
    Aletaha D; Alasti F; Smolen JS
    Ann Rheum Dis; 2013 Jan; 72(1):7-12. PubMed ID: 22915619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction.
    Smolen JS; Avila JC; Aletaha D
    Ann Rheum Dis; 2012 May; 71(5):687-93. PubMed ID: 22121130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.
    Smolen JS; Han C; Bala M; Maini RN; Kalden JR; van der Heijde D; Breedveld FC; Furst DE; Lipsky PE;
    Arthritis Rheum; 2005 Apr; 52(4):1020-30. PubMed ID: 15818697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes.
    Landewé R; van der Heijde D; Klareskog L; van Vollenhoven R; Fatenejad S
    Arthritis Rheum; 2006 Oct; 54(10):3119-25. PubMed ID: 17009230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial.
    Smolen JS; Van Der Heijde DM; St Clair EW; Emery P; Bathon JM; Keystone E; Maini RN; Kalden JR; Schiff M; Baker D; Han C; Han J; Bala M;
    Arthritis Rheum; 2006 Mar; 54(3):702-10. PubMed ID: 16508926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis.
    Lopez-Romero P; de la Torre I; Haladyj E; Aletaha D; Smolen JS
    Ann Rheum Dis; 2022 May; 81(5):622-631. PubMed ID: 35193872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression.
    Wells AF; Westhovens R; Reed DM; Fanti L; Becker JC; Covucci A; Keystone EC
    J Rheumatol; 2011 Nov; 38(11):2362-8. PubMed ID: 21885491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression of radiographic joint damage in rheumatoid arthritis: independence of erosions and joint space narrowing.
    Smolen JS; van der Heijde DM; Aletaha D; Xu S; Han J; Baker D; St Clair EW
    Ann Rheum Dis; 2009 Oct; 68(10):1535-40. PubMed ID: 18957487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: results from the GISEA register.
    Sebastiani M; Anelli MG; Atzeni F; Bazzani C; Farina I; Fedele AL; Favalli EG; Fineschi I; Cino N; Dal Forno I; Gasparini S; Cassarà E; Giardina R; Bruschi E; Addimanda O; Cassone G; Lopriore S; Sarzi-Puttini P; Filippini M; Pignatti F; Gremese E; Biggioggero M; Manganelli S; Amato G; Caimmi C; Salaffi F; Iannone F; Ferri C; Sandri G; Lapadula G; Gorla R; Govoni M; Ferraccioli G; Marchesoni A; Galeazzi M; Foti R; Carletto A; Cantini F; Triolo G; Epis OM; Salvarani C;
    Joint Bone Spine; 2014 Dec; 81(6):508-12. PubMed ID: 25082646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of radiographic joint damage in rheumatoid arthritis patients in DAS28 remission using single- or combined with methotrexate non biological disease-modifying antirheumatic drug therapy in routine clinical practice.
    Katayama K; Okubo T; Sato T; Ito H; Fukai R; Baba H
    Mod Rheumatol; 2015 Jan; 25(1):50-5. PubMed ID: 24983407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness of rituximab in combination with either methotrexate or leflunomide in the treatment of rheumatoid arthritis.
    Narváez J; Díaz-Torné C; Ruiz JM; Hernández MV; Torrente-Segarra V; Ros S; Rodriguez de la Serna A; Díaz-López C; Sanmartí R; Nolla JM
    Semin Arthritis Rheum; 2011 Dec; 41(3):401-5. PubMed ID: 21862107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE.
    Tak PP; Rigby W; Rubbert-Roth A; Peterfy C; van Vollenhoven RF; Stohl W; Healy E; Hessey E; Reynard M; Shaw T
    Ann Rheum Dis; 2012 Mar; 71(3):351-7. PubMed ID: 22012969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modelling the cost-effectiveness of combination therapy for early, rapidly progressing rheumatoid arthritis by simulating the reversible and irreversible effects of the disease.
    Stephens S; Botteman MF; Cifaldi MA; van Hout BA
    BMJ Open; 2015 Jun; 5(6):e006560. PubMed ID: 26059521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial.
    Tak PP; Rigby WF; Rubbert-Roth A; Peterfy CG; van Vollenhoven RF; Stohl W; Hessey E; Chen A; Tyrrell H; Shaw TM;
    Ann Rheum Dis; 2011 Jan; 70(1):39-46. PubMed ID: 20937671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study.
    van der Heijde D; Durez P; Schett G; Naredo E; Østergaard M; Meszaros G; De Leonardis F; de la Torre I; López-Romero P; Schlichting D; Nantz E; Fleischmann R
    Clin Rheumatol; 2018 Sep; 37(9):2381-2390. PubMed ID: 30078086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies.
    Keystone E; Emery P; Peterfy CG; Tak PP; Cohen S; Genovese MC; Dougados M; Burmester GR; Greenwald M; Kvien TK; Williams S; Hagerty D; Cravets MW; Shaw T
    Ann Rheum Dis; 2009 Feb; 68(2):216-21. PubMed ID: 18388156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and radiological dissociation of anti-TNF plus methotrexate treatment in early rheumatoid arthritis in routine care: results from the ABRAB study.
    Juhász P; Mester A; Biró AJ; Héjj G; Poór G
    BMC Musculoskelet Disord; 2014 Jul; 15():251. PubMed ID: 25059769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rheumatoid arthritis near remission: clinical rather than laboratory inflammation is associated with radiographic progression.
    Aletaha D; Alasti F; Smolen JS
    Ann Rheum Dis; 2011 Nov; 70(11):1975-80. PubMed ID: 21803751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year.
    Kremer JM; Blanco R; Brzosko M; Burgos-Vargas R; Halland AM; Vernon E; Ambs P; Fleischmann R
    Arthritis Rheum; 2011 Mar; 63(3):609-21. PubMed ID: 21360490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints.
    Aletaha D; Smolen JS
    Arthritis Rheum; 2011 Dec; 63(12):3702-11. PubMed ID: 21953215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.